BridgeBio Pharma, Inc. (NASDAQ: BBIO) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT BRIDGEBIO PHARMA, INC.

BridgeBio Pharma, Inc. (NASDAQ: BBIO)
Listen to this Section


$68.11
+0.7840 ( +1.16% ) 1.5M

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Market Data


Open $68.11
Previous Close $67.33
Volume 1.5M
Market Cap $13.19B
Day Range $66.50 - $69.47
52 Week Range $37.69 - $84.94
Shares Outstanding 195.86M
Change % +1.16%
Net Change ▲ 0.7840
Insider Ownership N/A
Exchange NASDAQ
SectorBasic Materials
IndustryPHARMACEUTICAL PREPARATIONS
IPO Year2019
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: 0.00

Date Type Amount Purchased Purchaser
No records found.

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Nov 10, 2025
4 Insider transactions 4 Nov 07, 2025
4 Insider transactions 1 Oct 31, 2025
8-k 8K-related 13 Oct 29, 2025
4 Insider transactions 1 Oct 29, 2025
8-k 8K-related 13 Oct 29, 2025
10-q Quarterly Reports 104 Oct 29, 2025
8-k 8K-related 13 Oct 27, 2025

Latest News


× Before browsing our site, please accept our cookies policy